Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shihchen Kuo

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Frontiers in Endocrinology|March 25, 2022
Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic ReviewChun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 3, 2022
Cost-effectiveness of carotid artery stenting vs endarterectomy: A simulationDeanna J Marriott, Shihchen Kuo, Wen Ye, et al.
Diabetes Care|May 20, 2026
Comment on Echouffo-Tcheugui et al. Is the Current Lifestyle Modification Approach to Diabetes Prevention in the U.S. a Success? Diabetes Care 2025;48:863-870Shihchen Kuo, Wen Ye, Laura N McEwen, et al.
Clinical Pharmacology and Therapeutics|April 18, 2021
Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney DiseaseChun-Ting Yang, Wei-Hung Lin, Lun-Jie Li, et al.
Cardiovascular Diabetology|July 10, 2024
Adaptation of risk prediction equations for cardiovascular outcomes among patients with type 2 diabetes in real-world settings: a cross-institutional study using common data model approachChun-Ting Yang, Kah Suan Chong, Chi-Chuan Wang, et al.
Diabetes Care|May 24, 2020
Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-upHsuan-Ying Chen, Shihchen Kuo, Pei-Fang Su, et al.
Pharmacoeconomics|September 12, 2025
Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness AnalysesKah Suan Chong, Chun-Ting Yang, Chi-Chuan Wang, et al.
Cardiovascular Diabetology|October 10, 2024
External validation and calibration of risk equations for prediction of diabetic kidney diseases among patients with type 2 diabetes in TaiwanHsuan-Yu Su, Thi Thuy Dung Nguyen, Wei-Hung Lin, et al.
Diabetes Care|November 20, 2024
Cost-Effectiveness of the National Diabetes Prevention Program: A Real-World, 2-Year Prospective StudyShihchen Kuo, Wen Ye, Di Wang, et al.
Environmental Health : a Global Access Science Source|November 6, 2020
Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysisPei-Fang Su, Fei-Ci Sie, Chun-Ting Yang, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Frontiers in Endocrinology|March 25, 2022
Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic ReviewChun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 3, 2022
Cost-effectiveness of carotid artery stenting vs endarterectomy: A simulationDeanna J Marriott, Shihchen Kuo, Wen Ye, et al.
Diabetes Care|May 20, 2026
Comment on Echouffo-Tcheugui et al. Is the Current Lifestyle Modification Approach to Diabetes Prevention in the U.S. a Success? Diabetes Care 2025;48:863-870Shihchen Kuo, Wen Ye, Laura N McEwen, et al.
Clinical Pharmacology and Therapeutics|April 18, 2021
Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney DiseaseChun-Ting Yang, Wei-Hung Lin, Lun-Jie Li, et al.
Cardiovascular Diabetology|July 10, 2024
Adaptation of risk prediction equations for cardiovascular outcomes among patients with type 2 diabetes in real-world settings: a cross-institutional study using common data model approachChun-Ting Yang, Kah Suan Chong, Chi-Chuan Wang, et al.
Diabetes Care|May 24, 2020
Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-upHsuan-Ying Chen, Shihchen Kuo, Pei-Fang Su, et al.
Pharmacoeconomics|September 12, 2025
Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness AnalysesKah Suan Chong, Chun-Ting Yang, Chi-Chuan Wang, et al.
Cardiovascular Diabetology|October 10, 2024
External validation and calibration of risk equations for prediction of diabetic kidney diseases among patients with type 2 diabetes in TaiwanHsuan-Yu Su, Thi Thuy Dung Nguyen, Wei-Hung Lin, et al.
Diabetes Care|November 20, 2024
Cost-Effectiveness of the National Diabetes Prevention Program: A Real-World, 2-Year Prospective StudyShihchen Kuo, Wen Ye, Di Wang, et al.
Environmental Health : a Global Access Science Source|November 6, 2020
Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysisPei-Fang Su, Fei-Ci Sie, Chun-Ting Yang, et al.
Pageof 7